You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CSF-1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Positron Emission Tomography, Alzheimer, Neurodegenerative Diseases Trial in Shanghai ([18F]CSF-23)

Recruiting
  • Positron Emission Tomography
  • +2 more
  • [18F]CSF-23
  • Shanghai, China
    Huashan Hospital
Nov 19, 2023

Unresectable Intrahepatic Cholangiocarcinoma Trial in Baltimore (Durvalumab, SNDX-6352)

Active, not recruiting
  • Unresectable Intrahepatic Cholangiocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Jan 10, 2023

Presbyopia Trial in United States (CSF-1, Vehicle)

Completed
  • Presbyopia
  • Newport Beach, California
  • +12 more
Dec 13, 2022

Presbyopia Trial in United States (CSF-1, Vehicle)

Completed
  • Presbyopia
  • Sun City, Arizona
  • +16 more
Jan 8, 2023

Presbyopia Trial in United States (CSF-1, Vehicle)

Completed
  • Presbyopia
  • Chandler, Arizona
  • +17 more
Jan 8, 2023

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

Assess CSF1R-related Leukoencephalopathy After Stem Cell

Enrolling by invitation
  • CSF1R-related Leukoencephalopathy
  • +3 more
    • Jacksonville, Florida
      Mayo Clinic in Florida
    Dec 7, 2021

    TNBC - Triple-Negative Breast Cancer, Breast Cancer Trial (Pembrolizumab, Radiation Therapy, Axatilimab)

    Not yet recruiting
    • TNBC - Triple-Negative Breast Cancer
    • Breast Cancer
    • (no location specified)
    Aug 4, 2022

    Prognostic Indicators of Response to CSF Shunt in Normotensive

    Recruiting
    • Cerebrospinal Fluid Levels of Amyloid Beta 1-42, H-tau and Phospho-tau Proteins
    • +3 more
    • Lumbar CSF protein marker determination
    • Valencia, Spain
    • +1 more
    Jun 13, 2023

    NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Carcinoma Breast
    • Suzhou, China
      Second Affiliated Hospital of Soochow University
    Oct 29, 2022

    Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma Trial in Boston (Sargramostim (GM-CSF), Pembrolizumab

    Recruiting
    • Unresectable Melanoma
    • +3 more
    • Sargramostim (GM-CSF)
    • Pembrolizumab (anti-PD-1)
    • Boston, Massachusetts
    • +1 more
    Jul 6, 2022

    Amyotrophic Lateral Sclerosis Trial (ARO-SOD1 Injection, Placebo: ARO-aCSF1 Injection)

    Not yet recruiting
    • Amyotrophic Lateral Sclerosis
    • ARO-SOD1 Injection
    • Placebo: ARO-aCSF1 Injection
    • (no location specified)
    Jul 8, 2023

    Sarcoma, Advanced Sarcoma, High Grade Sarcoma Trial in New York (DCC-3014, Avelumab)

    Active, not recruiting
    • Sarcoma
    • +6 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Oct 26, 2022

    Pancreatic Cancer Trial in Baltimore (Cyclophosphamide, GVAX, Pembrolizumab)

    Active, not recruiting
    • Pancreatic Cancer
    • Baltimore, Maryland
      Sidney Kimmel Comprehensive Cancer Center
    Jan 5, 2023

    Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer Trial (Q702, Pembrolizumab)

    Not yet recruiting
    • Esophageal Cancer
    • +3 more
    • (no location specified)
    Jun 27, 2022

    Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor Trial in Guangzhou (PEG-rhG-CSF)

    Recruiting
    • Granulocyte Colony-Stimulating Factor
    • PD-1 Inhibitor
    • Guangzhou, Guangdong, China
      Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
    Feb 2, 2022

    PD-1 Inhibitor, G-CSF Trial in Guangzhou (Camrelizumab, G-CSF)

    Recruiting
    • PD-1 Inhibitor
    • G-CSF
    • Guangzhou, Guangdong, China
      Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
    Feb 2, 2022

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Mar 29, 2023

    Acute Myeloid Leukemia, Myeloid Tumor Trial in Seattle (Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Myeloid Neoplasm
    • Biospecimen Collection
    • +9 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Sep 5, 2023

    Malignant Ascites Trial (Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy)

    Not yet recruiting
    • Malignant Ascites
    • (no location specified)
    Aug 11, 2022

    Carcinoma, Solid Tumor Trial in Suzhou (ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin)

    Not yet recruiting
    • Carcinoma
    • Solid Tumor
    • ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
    • Suzhou, China
      Second Affiliated Hospital of Soochow University
    Oct 26, 2023

    Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer Trial in Lyon, Toulouse (Pexidartinib, Durvalumab)

    Completed
    • Colorectal Cancer
    • +3 more
    • Lyon, France
    • +1 more
    Sep 2, 2021

    Peripheral T Cell Lymphoma Trial in Ann Arbor, Columbus, Madison (Nivolumab, cabiralizumab)

    Active, not recruiting
    Has Results
    • Peripheral T Cell Lymphoma
    • Ann Arbor, Michigan
    • +2 more
    Aug 13, 2021

    Acute Myeloid Leukemia Trial in Seattle (drug, biological, other)

    Active, not recruiting
    Has Results
    • Acute Myeloid Leukemia
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 10, 2022

    Stem Cell Transplant Complications Trial in Edmonton (Loratadine, Placebo)

    Not yet recruiting
    • Stem Cell Transplant Complications
    • Edmonton, Alberta, Canada
      Cross Cancer Institute
    Jun 13, 2022